BioNTech SE (NASDAQ:BNTX) Short Interest Update

BioNTech SE (NASDAQ:BNTX) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 2,020,000 shares, a decline of 16.2% from the October 15th total of 2,410,000 shares. Based on an average daily trading volume, of 997,700 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Baillie Gifford & Co. raised its stake in BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares in the last quarter. FMR LLC boosted its holdings in shares of BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after purchasing an additional 5,598,190 shares in the last quarter. Capital World Investors raised its holdings in shares of BioNTech by 0.5% during the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock worth $87,002,000 after buying an additional 4,369 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of BioNTech by 4.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after buying an additional 24,426 shares during the last quarter. Finally, Candriam S.C.A. grew its position in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after acquiring an additional 418,695 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Down 3.7 %

Shares of NASDAQ BNTX traded down $3.84 during trading hours on Friday, hitting $99.72. The company had a trading volume of 3,377,161 shares, compared to its average volume of 865,257. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The firm’s 50 day moving average is $113.54 and its 200-day moving average is $97.24. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the prior year, the business earned $0.73 EPS. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. Analysts predict that BioNTech will post -3.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. HC Wainwright increased their price objective on shares of BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a report on Monday, October 7th. TD Cowen dropped their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Bank of America raised their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Finally, Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $137.54.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.